27.7 C
New York
Wednesday, June 10, 2026

Tag: gene therapy

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. (SRPT) Investors with Substantial Losses Have Opportunity to Lead the Sarepta...

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta’s top executives with violations of the Securities Exchange Act of 1934.

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

[UPDATE] University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute

BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.

University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute

BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 27, 2025 /PRNewswire/ -- The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025...

EVA Pharma and BioPharma Town – Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office
EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.

Liver Disease Treatments: Global Market Forecast and Emerging Trends Through 2030

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON,...

Liver Disease Treatments: Global Market Forecast and Emerging Trends Through 2030

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON,...

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

- A word from our sponsors -

spot_img
HomeTagsGene therapy